SEC Form 4 · accession 0000899243-17-000698
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Faraz Ali
Officer — Chief Business Officer
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.50 | Jan 4, 2017 | A | 25,200 | A | — | Jan 3, 2027 | Common Stock | 25,200 | 25,200 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer.